NASDAQ:IMNM Immunome Q4 2024 Earnings Report $27.33 +0.26 (+0.96%) Closing price 04:00 PM EasternExtended Trading$27.30 -0.03 (-0.11%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immunome EPS ResultsActual EPS-$0.84Consensus EPS -$0.68Beat/MissMissed by -$0.16One Year Ago EPSN/AImmunome Revenue ResultsActual Revenue$2.74 millionExpected Revenue$3.07 millionBeat/MissMissed by -$330.00 thousandYoY Revenue GrowthN/AImmunome Announcement DetailsQuarterQ4 2024Date3/19/2025TimeBefore Market OpensConference Call DateWednesday, March 19, 2025Conference Call Time4:00PM ETUpcoming EarningsImmunome's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Immunome Earnings HeadlinesImmunome to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 2 at 7:45 AM | businesswire.comImmunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Moderate Buy" by AnalystsAugust 23, 2026 | americanbankingnews.comCould the Feds Freeze Your Bank Account?The Department of Justice recently argued in court that cash isn't property - a claim that could reshape how much control you actually have over the money in your bank account. If your balance isn't legally guaranteed to be yours, who really controls it? Three strategies may help you prepare before any restrictions take hold.September 2 at 1:00 AM | Priority Gold (Ad)Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The HorizonAugust 13, 2026 | seekingalpha.comImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid TumorsJuly 20, 2026 | businesswire.comWhat This Immunome Sale Means a Day Before a Big FDA MilestoneJuly 12, 2026 | fool.comSee More Immunome Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email. Email Address About ImmunomeImmunome (NASDAQ:IMNM) is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles. The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens. In parallel, Immunome is advancing additional candidates in solid tumors, including antibody–drug conjugates and immunomodulatory antibodies that aim to stimulate anti-tumor immune responses. Beyond oncology, the platform has been applied to infectious disease programs, where candidate antibodies against emerging viral threats have been identified and optimized for potential therapeutic or prophylactic use. Founded in the early 2000s and headquartered in Ann Arbor, Michigan, Immunome has grown from a privately held research operation into a publicly traded company listed on the Nasdaq exchange under the ticker “IMNM.” In 2021, the company completed its initial public offering, providing capital to support ongoing clinical development and platform expansion. Led by President and Chief Executive Officer Greg Bailey, Immunome maintains collaborations with academic institutions and industry partners to advance its pipeline and explore new therapeutic applications of its discovery platform.View Immunome ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestLilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond ObesityWendy’s Rally Fades After Trian Steps Back: Was It Ever Real?From High Dividend Growth to High Yield, These 3 Stocks Just Boosted Dividend PayoutsJ.M. Smucker Stock's Rally Has More Than Tariffs Behind ItUlta Beauty’s Earnings Beat Was Stronger Than the Stock’s ReactionNVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat Upcoming Earnings Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
